Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations From the Cancer Neuroscience Initiative Working Group

Ashley M Henneghan, Kathleen Van Dyk, Tara Kaufmann, Rebecca Harrison, Christopher Gibbons, Cobi Heijnen, Shelli R Kesler, Ashley M Henneghan, Kathleen Van Dyk, Tara Kaufmann, Rebecca Harrison, Christopher Gibbons, Cobi Heijnen, Shelli R Kesler

Abstract

Cancer and its treatments are associated with increased risk for cancer-related cognitive impairment (CRCI). Methods and measures used to study and assess self-reported CRCI (sr-CRCI), however, remain diverse, resulting in heterogeneity across studies. The Patient-Reported Outcomes Working Group has been formed to promote homogeneity in the methods used to study sr-CRCI. In this report, using a psychometric taxonomy, we inventory and appraise instruments used in research to measure sr-CRCI, and we consider advances in patient-reported outcome methodology. Given its psychometric properties, we recommend the Patient-Reported Outcome Measurement Information System Cognitive Function Short Form 8a for measurement of sr-CRCI in cancer patients and survivors, at a minimum, to increase scientific rigor and progress in addressing CRCI.

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

References

    1. Wefel JS, Kesler SR, Noll KR, Schagen SB.. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2):123–138.
    1. Janelsins MC, Kesler SR, Ahles TA, Morrow GR.. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102–113.
    1. Wefel JS, Vidrine DJ, Veramonti TL, et al.Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 2011;117(1):190–196.
    1. Vardy JL, Dhillon HM, Pond GR, et al.Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–4092.
    1. Sun M, Cole AP, Hanna N, et al.Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199(6):1417–1425.
    1. Buchbinder D, Kelly DL, Duarte RF, et al.Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018;53(5):535–555.
    1. Amidi A, Christensen S, Mehlsen M, Jensen AB, Pedersen AD, Zachariae R.. Long-term subjective cognitive functioning following adjuvant systemic treatment: 7-9 years follow-up of a nationwide cohort of women treated for primary breast cancer. Br J Cancer. 2015;113(5):794–801.
    1. Koppelmans V, Breteler MMB, Boogerd W, Seynaeve C, Gundy C, Schagen SB.. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30(10):1080–1086.
    1. Boykoff N, Moieni M, Subramanian SK.. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223.
    1. Robb C, Boulware D, Overcash J, Extermann M.. Patterns of care and survival in cancer patients with cognitive impairment. Crit Rev Oncol Hematol. 2010;74(3):218–224.
    1. Kesler SR, Blayney DW.. Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors. JAMA Oncol. 2016;2(2):185–192.
    1. Deprez S, Vandenbulcke M, Peeters R, et al.Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and Its relation with cognitive complaints. J Clin Oncol. 2014;32(19):2031–2038.
    1. McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ.. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(suppl):S117–S125.
    1. Kesler SR, Wefel JS, Hosseini SMH, Cheung M, Watson CL, Hoeft F.. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci USA. 2013;110(28):11600–11605.
    1. Koppelmans V, de Ruiter MB, van der Lijn F, et al.Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat. 2012;132(3):1099–1106.
    1. de Ruiter MB, Reneman L, Boogerd W, et al.Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–1219.
    1. Stouten-Kemperman MM, de Ruiter MB, Koppelmans V, Boogerd W, Reneman L, Schagen SB.. Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type. Brain Imaging Behav. 2015;9(2):275–284.
    1. Stouten-Kemperman MM, de Ruiter MB, Boogerd W, Veltman DJ, Reneman L, Schagen SB.. Very late treatment-related alterations in brain function of breast cancer survivors. J Int Neuropsychol Soc. 2015;21(1):50–61.
    1. Ahles TA, Saykin AJ, McDonald BC, et al.Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434–4440.
    1. Collins B, Mackenzie J, Tasca GA, Scherling C, Smith A.. Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy. J Int Neuropsychol Soc. 2014;20(4):370–379.
    1. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FSAM.. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98(23):1742–1745.
    1. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA.. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–3356.
    1. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA.. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–2299.
    1. Nelson WL, Suls J.. New approaches to understand cognitive changes associated with chemotherapy for non-central nervous system tumors. J Pain Symptom Manage. 2013;46(5):707–721.
    1. Wefel JS, Vardy J, Ahles T, Schagen SB.. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–708.
    1. Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C.. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926–934.
    1. Horowitz TS, Suls J, Trevino M.. A call for a neuroscience approach to cancer-related cognitive impairment. Trends Neurosci. 2018;41(8):493–496.
    1. Janelsins MC, Heckler CE, Peppone LJ, et al.Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35(5):506–514.
    1. Bray VJ, Dhillon HM, Vardy JL.. Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv. 2018;12(4):537–559.
    1. Smith TG, Castro KM, Troeschel AN, et al.The rationale for patient-reported outcomes surveillance in cancer and a reproducible method for achieving it. Cancer. 2016;122(3):344–351.
    1. Henneghan A, Stuifbergen A, Becker H, Kesler S, King E.. Modifiable correlates of perceived cognitive function in breast cancer survivors up to 10 years after chemotherapy completion. J Cancer Surviv. 2018;12(2):224–233.
    1. Merriman JD, Sereika SM, Brufsky AM, et al.Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psychooncology. 2017;26(1):44–52.
    1. Kalin NH. Mechanisms underlying the early risk to develop anxiety and depression: a translational approach. Eur Neuropsychopharmacol. 2017;27(6):543–553.
    1. Brakowski J, Spinelli S, Dörig N, et al.Resting state brain network function in major depression—depression symptomatology, antidepressant treatment effects, future research. J Psychiatr Res. 2017;92:147–159.
    1. Petrican R, Saverino C, Shayna Rosenbaum R, Grady C.. Inter-individual differences in the experience of negative emotion predict variations in functional brain architecture. Neuroimage. 2015;123:80–88.
    1. Yang X, Liu J, Meng Y, et al.Network analysis reveals disrupted functional brain circuitry in drug-naive social anxiety disorder. Neuroimage. 2019;190:213–223.
    1. Sheline YI, Price JL, Yan Z, Mintun MA.. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci USA. 2010;107(24):11020–11025.
    1. Apple AC, Ryals AJ, Alpert KI, et al.Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. Neuroimage Clin. 2017;14:685–691.
    1. Apple AC, Schroeder MP, Ryals AJ, et al.Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. Neuroimage Clin. 2018;20:110–118.
    1. Kesler SR, Kent JS, O’Hara R.. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447–1453.
    1. Kesler SR, Watson C, Koovakkattu D, et al.Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav. 2013;7(4):501–510.
    1. O’Farrell E, Smith A, Collins B.. Objective-subjective disparity in cancer-related cognitive impairment: Does the use of change measures help reconcile the difference? Psychooncology. 2017;26(10):1667–1674.
    1. Deprez S, Kesler SR, Saykin AJ, Silverman DHS, de Ruiter MB, McDonald BC.. International Cognition and Cancer Task Force recommendations for neuroimaging methods in the study of cognitive impairment in non-CNS cancer patients. J Natl Cancer Inst. 2018;110(3):223–231.
    1. Winocur G, Berman H, Nguyen M, et al.Neurobiological mechanisms of chemotherapy-induced cognitive impairment in a transgenic model of breast cancer. Neuroscience. 2018;369:51–65.
    1. Mokkink LB, Terwee CB, Patrick DL, et al.The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63(7):737–745.
    1. Polit DE, Beck CT, Nursing Research: Generating and Assessing Evidence for Nursing Practice 11 ed. Philadelphia, PA: Wolters Kluwer; 2021.
    1. Aaronson NK, Ahmedzai S, Bergman B, et al.The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
    1. Poppelreuter M, Weis J, Bartsch HH.. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol. 2009;27(2):274–296.
    1. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR.. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21(1):1–16.
    1. Schagen SB, Das E, Vermeulen I.. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology. 2012;21(10):1132–1135.
    1. Vom Hofe A, Mainemarre G, Vannier LC.. Sensitivity to everyday failures and cognitive inhibition: Are they related? Eur Rev Appl Psychol. 1998;48(1):49–56.
    1. Bridger RS, Johnsen SA, Brasher K.. Psychometric properties of the Cognitive Failures Questionnaire. Ergonomics. 2013;56(10):1515–1524.
    1. Gokal K, Munir F, Ahmed S, Kancherla K, Wallis D.. Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial. PLoS One. 2018;13(11):e0206874.
    1. Wagner LI, Sweet JJ, Butt Z, Lai JS, Cella D.. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7(6):W32–W39.
    1. Wagner LI. FACT-Cog Version 3 Psychometric properties. Presented at ICCTF Workshop; October 2008; Venice, Italy.
    1. Myers JS, Mitchell M, Krigel S, et al.Qigong intervention for breast cancer survivors with complaints of decreased cognitive function. Support Care Cancer. 2019;27(4):1395–1403.
    1. Mihuta ME, Green HJ, Shum DHK.. Web-based cognitive rehabilitation for survivors of adult cancer: a randomised controlled trial. Psychooncology. 2018;27(4):1172–1179.
    1. Tong T, Pei C, Chen J, Lv Q, Zhang F, Cheng Z.. Efficacy of acupuncture therapy for chemotherapy-related cognitive impairment in breast cancer patients. Med Sci Monit. 2018;24:2919–2927.
    1. Van Dyk K, Ganz PA, Ercoli L, Petersen L, Crespi CM.. Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient’s assessment of own functioning inventory. Support Care Cancer. 2016;24(12):4939–4949.
    1. Bell MJ, Terhorst L, Bender CM.. Psychometric analysis of the Patient Assessment of Own Functioning Inventory in women with breast cancer. J Nurs Meas. 2013;21(2):320–334.
    1. Wu LM, Amidi A, Tanenbaum ML, et al.Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer. 2018;26(6):1917–1926.
    1. Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A.. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol. 1994;16(1):93–104.
    1. Cimprich B, Visovatti M, Ronis DL.. The Attentional Function Index—a self-report cognitive measure. Psychooncology. 2011;20(2):194–202.
    1. Roth RM, Lance CE, Isquith PK, Fischer AS, Giancola PR.. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function-Adult version in healthy adults and application to attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2013;28(5):425–434.
    1. Roth RM, Isquith PK, Gioia G.. Behavioral Rating Inventory of Executive Function - Adult Version. Lutz, FL: Psychological Assessment Resources; 2005.
    1. Kesler S, Hosseini S, Cheung M, Koovakkattu D. Influence of executive function training on prefrontal functional networks in healthy adults. Paper presented at Society for Neuroscience; 2013; San Diego, CA.
    1. Walentynowicz M, Schneider S, Stone AA.. The effects of time frames on self-report. PLoS One. 2018;13(8):e0201655.
    1. Cheung YT, Foo YL, Shwe M, et al.Minimal clinically important difference (MCID) for the Functional Assessment of Cancer Therapy: Cognitive Function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014;67(7):811–820.
    1. Zimmerman P, Messner C, Poser U, Sedelmaier P.. Ein Fragebogen Erlebter Defizite Der Aufmerksamkeit [Questionnaire for Experienced Attention Deficits]. Unpublished Manuscript. Germany: University of Freiburg; 1991.
    1. Gioia GA, Isquith PK, Guy SC, Kenworthy L.. BRIEF 2: Behavior Rating Inventory of Executive Function 2nd ed. Lutz, FL: Psychological Assessment Resources; 2015.
    1. Brown TE. Brown Executive Function/Attention Scales. Pearson; 2018.
    1. Conners CK. Conners 3rd ed. Pearson; 2008.
    1. Cheung YT, Krull KR.. Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: a systematic review. Neurosci Biobehav Rev. 2015;53:108–120.
    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA.. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–2765.
    1. Salthouse TA. Neuroanatomical substrates of age-related cognitive decline. Psychol Bull. 2011;137(5):753–784.
    1. Mandelblatt JS, Hurria A, McDonald BC, et al.; Thinking and Living With Cancer Study. Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know? Semin Oncol. 2013;40(6):709–725.
    1. Pergolotti M, Battisti NML, Padgett L, et al.Embracing the complexity: older adults with cancer-related cognitive decline—a Young International Society of Geriatric Oncology position paper. J Geriatr Oncol. 2020;11(2):237–243.
    1. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B.. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130(6):439–451.
    1. Mohile SG, Dale W, Somerfield MR, et al.Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326–2347.
    1. Portenoy RK, Thaler HT, Kornblith AB, et al.Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994;3(3):183–189.
    1. Kurita GP, Sjøgren P, Ekholm O, et al.Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol. 2011;29(10):1297–1303.
    1. Pergolizzi D, Crespo I.. Recognition of cognitive complaints for patients with advanced cancer. Support Care Cancer. 2020;28(11):5055–5057.
    1. Douw L, Klein M, Fagel SS, et al.Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–818.
    1. Armstrong TS, Mendoza T, Gring I, et al.Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006;80(1):27–35.
    1. Taphoorn MJ, Claassens L, Aaronson NK, et al.The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: a phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG. J Clin Oncol. 2008;26(15_suppl):2041–2041.
    1. Thavarajah N, Bedard G, Zhang L, et al.Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases. Support Care Cancer. 2014;22(4):1017–1028.
    1. Teresi JA. Overview of quantitative measurement methods: equivalence, invariance, and differential item functioning in health applications. Med Care. 2006;44(11)(suppl 3):S39–S49.
    1. Cella D, Yount S, Rothrock N, et al.; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45(5)(suppl 1):S3–S11.
    1. Garcia SF, Cella D, Clauser SB, et al.Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007;25(32):5106–5112.
    1. Lord FM. Applications of Item Response Theory to Practical Testing Problems. Mahwah, NJ: Lawrence Erlbaum Associates; 1980.
    1. Cella D, Riley W, Stone A, et al.; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179–1194.
    1. Fries JF, Bruce B, Cella D.. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol. 2005;23(5)(suppl 39):S53–S57.
    1. Lai JS, Butt Z, Zelko F, et al.Development of a parent-report cognitive function item bank using item response theory and exploration of its clinical utility in computerized adaptive testing. J Pediatr Psychol. 2011;36(7):766–779.
    1. Gibbons C, Bower P, Lovell K, Valderas J, Skevington S.. Electronic quality of life assessment using computer-adaptive testing. J Med Internet Res. 2016;18(9):e240.
    1. Choi SW, Reise SP, Pilkonis PA, Hays RD, Cella D.. Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res. 2010;19(1):125–136.
    1. PROMIS® Instrument Development and Validation Scientific Standards Version 2.0. National Institutes of Health: Health Measures; 2013.
    1. Lai JS, Wagner LI, Jacobsen PB, Cella D.. Self-reported cognitive concerns and abilities: Two sides of one coin? Psychooncology. 2014;23(10):1133–1141.
    1. Valentine TR, Weiss DM, Jones JA, Andersen BL.. Construct validity of PROMIS® Cognitive Function in cancer patients and noncancer controls. Health Psychol. 2019;38(5):351–358.
    1. Lai JS, Kupst MJ, Beaumont JL, et al.Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to measure symptom burden reported by patients with brain tumors. Pediatr Blood Cancer. 2019;66(3):e27526.
    1. Stachler RJ, Schultz LR, Nerenz D, Yaremchuk KL.. PROMIS evaluation for head and neck cancer patients: a comprehensive quality-of-life outcomes assessment tool. Laryngoscope. 2014;124(6):1368–1376.
    1. Myers JS, Kahya M, Mitchell M, et al.Pupillary response: cognitive effort for breast cancer survivors. Support Care Cancer. 2019;27(3):1121–1128.
    1. Ruark J, Mullane E, Cleary N, et al.Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2020;26(1):34–43.
    1. Jensen RE, Potosky AL, Moinpour CM, et al.United States population-based estimates of Patient-Reported Outcomes Measurement Information System symptom and functional status reference values for individuals with cancer. J Clin Oncol. 2017;35(17):1913–1920.
    1. Iverson GL, Marsh JM, Connors EJ, Terry DP.. Normative reference values, reliability, and item-level symptom endorsement for the PROMIS® v2.0 cognitive function-short forms 4a, 6a and 8a. Arch Clin Neuropsychol. 2021;acaa128.doi: 10.1093/arclin/acaa128.
    1. Fieo R, Ocepek-Welikson K, Kleinman M, et al.Measurement Equivalence of the Patient Reported Outcomes Measurement Information System® (PROMIS®) applied cognition - general concerns, short forms in ethnically diverse groups. Psychol Test Assess Model. 2016;58(2):255–307.
    1. Winocur G, Johnston I, Castel H.. Chemotherapy and cognition: International Cognition and Cancer Task Force recommendations for harmonising preclinical research. Cancer Treat Rev. 2018;69:72–83.
    1. Basch E, Deal AM, Kris MG, et al.Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–565.
    1. Meyers CA, Abbruzzese JL.. Cognitive functioning in cancer patients: effect of previous treatment. Neurology. 1992;42(2):434–436.
    1. Johns SA, Von Ah D, Brown LF, Beck-Coon K, Talib T, Alyea JM, Monahan PO, Tong Y, Willhelm L, & Giesler R.B. Randomized controlled pilot trial of mindfulness-based stress reduction for breast and colorectal cancer survivors: effects on cancer-related cognitive impairment. Journal of Cancer Survivorship. 2016;10(3):437–448. 10.1007/s11764-015-0494-3.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться